Navigation Links
The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimer's Disease Innovation, Nobel Laureate Elie Wiesel
Date:7/9/2012

NEW YORK, July 9, 2012 /PRNewswire/ -- The Galien Foundation today announced the formal program of presenters and panels for its Third Galien Forum, scheduled for Tuesday, October 16, 2012 at the Alexandria Center for Life Science in New York City.  The Galien Forum, conducted in conjunction with the prestigious Prix Galien Awards, features roundtable debates focusing on critical, global healthcare issues and challenges.  This year's program includes a panel of CEO emeriti making rare public appearances: P. Roy Vagelos, M.D. (Merck, current Chairman of Regeneron), Fred Hassan (Schering-Plough, Pharmacia, current Chairman of Bausch + Lomb) and Bernard Poussot (Wyeth). 

(Logo:  http://photos.prnewswire.com/prnh/20120416/NY87735LOGO )

Additionally, a Panel on "The Ethics of Innovation" will be moderated by Elie Wiesel, Andrew W. Mellon Professor of Humanities and Professor of Religion, College of Arts and Sciences, Boston University, best-selling author, and Nobel Peace Prize Laureate.  In a testament to the global reach and implications of biomedical innovation, Guido Rasi, Executive Director, European Medicines Agency, will provide his perspective during the opening Plenary Session.

"We are so proud to have attracted biopharmaceutical leaders, researchers, patient advocates, health policy experts and ethicists at the very top of their fields to contribute their expertise and wisdom to our Third Galien Forum," said Bruno Cohen, Galien Foundation Chairman.  "It is only through coming together for conversations and working collaboratively that we will be able to address the challenging global healthcare issues facing scientific, medical and technological innovation."

In addition to keynote sessions, there will be six roundtable panel presentations, including "Alzheimer's Innovation and the White House 2025 Mandate: What Will It Take to Find a Treatment," which features a "who's who" of Alzheimer's disease research, advocacy and health policy:

  • Russell Katz, M.D., Director, FDA Division of Neurological Drug Products within the Center for Drug Evaluation and Research (CDER);
  • Stephen Hume, M.D., a leading clinician and a patient with early onset Alzheimer's disease himself;
  • Bill Potter, M.D., Ph.D., Senior Advisor, National Institutes of Mental Health;
  • Dennis Selkoe, M.D., Co-Director, Center for Neurological Diseases, Brigham and Women's Hospital and Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School;
  • Bill Thies, M.D., Chief Medical and Scientific Officer, Alzheimer's Association; 
  • Meryl Comer, President, Geoffrey Beene Foundation, Alzheimer's Initiative; and 
  • Michael Rosenblatt, M.D., Executive Vice President and Chief Medical Officer, Merck, who will serve as panel moderator.

The Galien Foundation also disclosed today that nomination submissions for the 2012 Prix Galien USA Awards has reached an all-time high of 30 submissions, reflecting both the burgeoning levels of biopharmaceutical innovation in the United States, and recognition that the Prix Galien Awards represent the highest accolade for research and development – the biomedical industry's equivalent of the Nobel Prize.

"The drive to innovate starts with an idea of a scientist who understands the latest new knowledge from basic research and the unmet medical needs of patients," commented P. Roy Vagelos, M.D., Chairman of Regeneron Pharmaceuticals, retired Chairman and Chief Executive Officer at Merck and chair of the Prix Galien USA Awards Committee.  "When new understanding permits a new attack on an important disease, it is possible to improve outcomes for patients."

About the Galien Foundation and the Prix Galien Awards

The mission of the Galien Foundation is to serve as a vehicle for the open exchange of ideas that drive science and new innovations.  The Foundation's third major forum will be held at the Alexandria Center for Life Science on the morning of October 16, 2012, and will feature round table debates focusing on critical, global healthcare issues and challenges.

The Prix Galien Awards were created to honor medical research and pharmacology for outstanding efforts to improve the human condition though approval of innovative treatments and medicines.  The winners are selected by a preeminent scientific and learned committee that included several Nobel Laureates. Past product award recipients include; Prevnar 13® (Pfizer 2011), Stelara® (Janssen 2011), Prolia®/XGEVA® (Amgen 2011), Coartem® (Novartis 2010), RotaTeq® (Merck 2010), xTAG® (Luminex 2010), Gleevec® (Novartis 2009), Nplate® (Amgen 2009), Promacta® (GSK 2009), Cellsearch® (Veridex 2009), Isentress® (Merck 2009), Selzentry® (Pfizer 2008), Soliris® (Alexion 2008), Infuse® (Wyeth 2008), Revlimid® (Celgene 2008), Januvia® (Merck 2007), Chantix® (Pfizer 2007), Humira® (Abbott 2007) and Gardasil® (Merck 2007). 

The Pro Bono Humanum Award recognizes exemplary efforts by individuals and organizations in helping mankind.  The award will be presented by Professor Elie Wiesel, a Nobel Prize Laureate.  Previous winners of the award include: Professor Paul Farmer (2011), President Bill Clinton and Philippe Douste-Blazy (2010); Professors Barry Bloom and Jeffrey Sachs (2009), Sheldon Segal and the Population Council (2008); and Dr. P. Roy Vagelos (2007). 

For more information visit www.galienfoundation.org

 


'/>"/>
SOURCE Prix Galien USA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Galien Foundation Announces New "Best Medical Technology" Award Category for 2012 Prix Galien USA Awards Program
2. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
3. The Michael J. Fox Foundation Launches The $14 Million-Edmond J. Safra Core Programs for PD Research
4. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
7. AUA Foundation Launches Campaign to Address Stigma of Overactive Bladder
8. Elsevier and Russias Skolkovo Foundation Sign Access Agreement to SciVerse Scopus and SciVal Funding
9. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
10. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
11. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Engineers at the ... because it produces the same kind of electrical energy that the body uses. ... of moving electrons. This flow of electrons out of the battery is generated by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
Breaking Medicine News(10 mins):